NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today ...

Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive lymphoma or tumor of the brain. While ...

Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, announced today it has received a research grant ...

How can one city’s election shake up the real estate market 1,300 miles away? According to Miami developers, it’s all because ...

Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...

Queen’s researcher Dr. Sébastien Talbot, whose recent Nature paper examines the connection between nerves and tumour response, is advancing the field of cancer neuroscience.

It’s one of the tenets of physical fitness, so why is flexibility overlooked by researchers and the average person putting on ...

Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called ...

Launched in the summer of 1982, Diet Coke was marketed as a healthier alternative to regular soda - without the sugar or ...

Bristol Myers Squibb (NYSE:BMY) in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added ...

HOUSTON, NOV. 12, 2025 ― The University of Texas MD Anderson Cancer Center today launches its ...

Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today ...